)
Jasper Therapeutics (JSPR) investor relations material
Jasper Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q3 net loss was $144.5m, including a $129.5m acquired IPR&D charge; $8.0m of Mirador drug-supply revenue was offset by $8.0m in related costs.
July acquisition of Kira expanded the pipeline with KP104, KP701 and discovery-stage complement programs; the portfolio also includes briquilimab and vensobafusp alfa.
Financial highlights
Q3 revenue was $8.0m, operating loss was $144.2m and net loss was $144.5m, versus $18.7m net loss in Q3 2025.
9M revenue was $8.0m, operating loss was $164.3m and net loss was $148.4m, versus $66.7m net loss in 9M 2025.
Q3 R&D expense fell 42% YoY to $8.3m and G&A rose 33% to $6.4m; 9M R&D fell 63% to $19.3m and G&A fell 4% to $15.6m.
Cash and cash equivalents were $135.3m at Sept. 30, 2026, versus $28.7m at Dec. 31, 2025; accumulated deficit was $465.1m.
Outlook and guidance
KP104 interim IgAN Stage 1 data expected Q4 2026, with updated data in Q1 2027; initial C3G/IC-MPGN data expected Q2 2027 and FSGS data Q3 2027.
First FSGS expansion-cohort patients expected to be dosed Q1 2027; initial briquilimab SCID conditioning study data expected Q4 2026, with SCID pre-BLA meeting next steps expected Q1 2027.
KP104 pre-IND meeting next steps for PNH expected H1 2027; a new indication announcement is anticipated by end-2026. KP701 CTA or IND filing expected Q1 2027 and first-in-human data Q3 2027.
Discovery-stage complement candidate selection expected mid-2027; R&D expense expected to increase substantially as programs advance.
- Preferred-stock conversion votes could reshape ownership while Nasdaq compliance remains at risk.JSPR
Proxy filing - A 284.0M-share resale shelf amid conversion, dilution and going-concern risks.JSPR
Registration filing - Conversion votes could unlock major dilution while addressing Nasdaq listing risks.JSPR
Proxy filing - Merger creates a well-funded, multi-asset immunology pipeline with major clinical milestones ahead.JSPR
H.C. Wainwright 28th Annual Global Investment Conference - Shareholders will vote on a reverse stock split, share increase, and adjournment to support compliance and growth.JSPR
Proxy filing - Shareholders will vote virtually on a reverse split and share increase to support compliance and growth.JSPR
Proxy filing - Net loss narrowed, but going concern risk persists despite Kira acquisition and $132M financing.JSPR
Q2 2026 - Briquilimab shows high efficacy and durability in urticaria, with pivotal Beacon data expected soon.JSPR
Stifel 2024 Healthcare Conference - Misdiagnosis explained BEACON anomalies; briquilimab showed efficacy and safety in asthma.JSPR
Study Result
)
)
)
)
)
)
)
)